By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Fresh data on Biotechnology are presented in a new report. According to news reporting originating from Tartu, Estonia, by NewsRx correspondents, research stated, "The successful applicability of gene therapy approaches will heavily rely on the development of efficient and safe nonviral gene delivery vectors, for example, cell-penetrating peptides (CPPs). CPPs can condense oligonucleotides and plasmid DNA (pDNA) into nanoparticles, thus allowing the transfection of genetic material into cells."
Our news editors obtained a quote from the research from the University of Tartu, "However, despite few promising attempts, CPP-mediated pDNA delivery has been relatively inefficient due to the unfavorable nanoparticle characteristics or the nanoparticle entrapment to endocytic compartments. In many cases, both of these drawbacks could be alleviated by modifying CPPs with a stearic acid residue, as demonstrated in the delivery of both the pDNA and the short oligonucleotides. In this study, PepFect14 (PF14) peptide, previously used for the transport of shorter oligonucleotides, is demonstrated to be suited also for the delivery of pDNA. It is shown that PF14 forms stable nanoparticles with pDNA with a negative surface charge and size of around 130-170 nm. These nanoparticles facilitate efficient gene delivery and expression in a variety of regular adherent cell lines and also in difficult-to-transfect primary cells. Uptake studies indicate that PF14/pDNA nanoparticles are utilizing class A scavenger receptors (SCARA) and caveolae-mediated endocytosis as the main route for cellular internalization."
According to the news editors, the research concluded: "Conclusively, PF14 is an efficient nonviral vector for gene delivery."
For more information on this research see: PepFect14 peptide vector for efficient gene delivery in cell cultures. Molecular Pharmaceutics, 2013;10(1):199-210. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
The news editors report that additional information may be obtained by contacting K.L. Veiman, Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia. Additional authors for this research include I. Mager, K. Ezzat, H. Margus, T. Lehto, K. Langel, K. Kurrikoff, P. Arukuusk, J. Suhorutenko, K. Padari, M. Pooga, T. Lehto and U Langel (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Tartu, Europe, Estonia, Peptides, Proteins, Proteomics, Gene Therapy, Nanoparticle, Bioengineering, Nanotechnology, Emerging Technologies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC